By PPN News Staff
The FDA approved filgrastim-aafi (Nivestym, Pfizer), a biosimilar of Amgen’s Neupogen (filgrastim) for all eligible indications as the reference product.
The drug approval was based on a review of a comprehensive data package and the totality of the evidence demonstrating a high degree of similarity between filgrastim-aafi and the reference product.